Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

SITAGLIPTIN PHOSPHATE

SITAGLIPTIN PHOSPHATE

Standard Dose
25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview SITAGLIPTIN PHOSPHATE is listed in Drugs@FDA under application 211073 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient SITAGLIPTIN PHOSPHATE Form and strength TABLET; ORAL - 25MG Sponsor MACLEODS PHARMS LTD Submission history Latest submission status date: 2025-04-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview SITAGLIPTIN PHOSPHATE is listed in Drugs@FDA under application 211073 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient SITAGLIPTIN PHOSPHATE Form and strength TABLET; ORAL - 25MG Sponsor MACLEODS PHARMS LTD Submission history Latest submission status date: 2025-04-02 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
SITAGLIPTIN PHOSPHATE (SITAGLIPTIN PHOSPHATE) | Drug Monograph | MedicHelpline